EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting

Ibraheem Othman iD, Seyedeh Zahra Mona Moossavi, Samaneh Bayati, Yi Sin Chang iD, Shubrandu Sanjoy, Karolina Grzyb, Eric Sy iD, Kayla Cropper, Sandy Kassir, Waleed Sabry iD

Current Oncology · 2025

DOI: 10.3390/curroncol32060296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Ibraheem Othman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Innovative Medicine, Johnson & Johnson Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term clinical trials and real-world data have established a comprehensive risk–benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy.

Methods

We retrospectively assessed the incidence of AEs of special interest and management strategies in all patients treated with ibrutinib for chronic lymphocytic leukemia (CLL) in Saskatchewan, Canada, since 2014.

Results

Among 187 patients (median age 75.7 years, 63% male), the median time from ibrutinib treatment initiation to data cutoff was 3.1 years. Approximately two-thirds of patients received ibrutinib for relapsed CLL (33.7% second-line and 32.6% third-line and beyond), with 33.7% receiving it first-line. All patients initiated ibrutinib as monotherapy at 420 mg. AEs of interest were observed in 81.3% of patients, with 42.8% experiencing ≥2 AEs. No grade 5 AEs were reported. Among the 284 first-onset AEs observed in 152 patients, 90.8% were successfully managed, allowing treatment continuation. The median time to successful management ranged from 27.0 days (range: 12.5–73.0) for infections to 84.0 days (range: 55.0–141.0) for hypertension. Both AE and discontinuation rates were comparable or favourable to previous reports.

Conclusion

This real-world analysis suggests that ibrutinib may be safely used in the majority of CLL patients encountered in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellPyrazolesPyrimidinesHumansAdeninePiperidinesMaleAgedFemaleAged, 80 and overRetrospective StudiesIncidenceMiddle AgedTreatment OutcomeCanada

Stichwörter der Autor:innen

adverse eventschronic lymphocytic leukemiaibrutinibtreatment discontinuation

Substanzen

ibrutinibAdeninePiperidinesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada.
  • College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
  • Epidemiology and Performance Measurement, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada.
  • Research Department, Saskatchewan Health Authority, Regina, SK S7K 0M7, Canada.
  • Department of Critical Care, Saskatchewan Health Authority, Regina, SK S4P 0W5, Canada.
  • Division of Hematology, Department of Medical Oncology and Hematology, Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada.

ORCID-Profile: Ibraheem Othman, Yi Sin Chang, Eric Sy, Waleed Sabry

Förderung

  • Johnson & Johnson Innovative Medicine
  • Johnson & Johnson Innovative Medicine

Zitieren

APA

Othman, I., Moossavi, S. Z. M., Bayati, S., Chang, Y. S., Sanjoy, S., Grzyb, K., Sy, E., Cropper, K., Kassir, S., & Sabry, W. (2025). Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Current Oncology. https://doi.org/10.3390/curroncol32060296

Vancouver

Othman I, Moossavi SZM, Bayati S, Chang YS, Sanjoy S, Grzyb K, et al. Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Current Oncology. 2025. doi:10.3390/curroncol32060296

BibTeX
@article{Othman2025,
  author = {Othman, Ibraheem and Moossavi, Seyedeh Zahra Mona and Bayati, Samaneh and Chang, Yi Sin and Sanjoy, Shubrandu and Grzyb, Karolina and Sy, Eric and Cropper, Kayla and Kassir, Sandy and Sabry, Waleed},
  title = {Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32060296}
}
Kostenlos starten →